This is the artifact for the ICSE 2021 paper "Smart Contract Security: a Practitioners' Perspective". What the artifact does: 1) an interview guide that we used for our semi-
Introduction: Erythropoiesis-stimulating agents (ESAs) are the current standard of care for anemia due to chronic kidney disease (CKD) in patients not undergoing dialysis. Molidustat, an
Interventions: experimental group:Apatinib combined with oxaliplatin and capecitabine (XELOX) g Primary outcome(s): Disease free survival Study Design: Single arm